Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy

We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 da...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 1999-01, Vol.28 (Supplement-1), p.S57-S65
Hauptverfasser: Joesoef, M. R., Schmid, G. P., Hillier, S. L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S65
container_issue Supplement-1
container_start_page S57
container_title Clinical infectious diseases
container_volume 28
creator Joesoef, M. R.
Schmid, G. P.
Hillier, S. L.
description We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.
doi_str_mv 10.1086/514725
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69593846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4460675</jstor_id><sourcerecordid>4460675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</originalsourceid><addsrcrecordid>eNpNkFtPJCEQhYlZo66XX2BMP5h9a4WmoWHfdLLrJSbeRrPZF1LdDYr2NCMwXv69jD1RE5Kq1Pk4BQehLYL3CBZ8n5GyKtgSWiOMVjlnkvxIPWYiLwUVq-hnCA8YEyIwW0GrBONCEILXkDqEJmpvoctu4c72LtjwO7vSz1a_ZM5kY68hTnQfs_NptK4PGfRtduFiGs0vjTrb2yY1J32b6oAY57PxvfYwfdtAywa6oDcXdR3d_P0zHh3nZ-dHJ6ODs7yhksW8Te8xvAZT0NpQxmhRt5Uk6VeAQfJSN-lQ4LKV3AhWkUKWpC5ELQDThlV0Hf0afKfePc10iGpiQ6O7DnrtZkFxySQVJf8CG-9C8NqoqbcT8G-KYDWPUg1RJnBn4TirJ7r9hg3ZJWB3AUBICRgPfWPDF8cFwx_Y9oA9hOj8p1yWHPNqviYfZBuifv2UwT8qXtGKqeN__xU5wsXh9fhSndJ3SziSSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69593846</pqid></control><display><type>article</type><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</creator><creatorcontrib>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</creatorcontrib><description>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/514725</identifier><identifier>PMID: 10028110</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Bacterial diseases ; Bacterial diseases of the genital system ; Bacterial vaginosis ; Biological and medical sciences ; Cream ; Dosage ; Experimentation ; Female ; Gels ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; Male ; Medical sciences ; Placebos ; Pregnancy ; Pregnancy outcome ; Sexually transmitted diseases ; Vaginosis, Bacterial - drug therapy</subject><ispartof>Clinical infectious diseases, 1999-01, Vol.28 (Supplement-1), p.S57-S65</ispartof><rights>Copyright 1999 The Infectious Diseases Society of America</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</citedby><cites>FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4460675$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4460675$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,803,4047,4048,23928,23929,25138,27922,27923,58015,58248</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1685010$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10028110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joesoef, M. R.</creatorcontrib><creatorcontrib>Schmid, G. P.</creatorcontrib><creatorcontrib>Hillier, S. L.</creatorcontrib><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</description><subject>Bacterial diseases</subject><subject>Bacterial diseases of the genital system</subject><subject>Bacterial vaginosis</subject><subject>Biological and medical sciences</subject><subject>Cream</subject><subject>Dosage</subject><subject>Experimentation</subject><subject>Female</subject><subject>Gels</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Placebos</subject><subject>Pregnancy</subject><subject>Pregnancy outcome</subject><subject>Sexually transmitted diseases</subject><subject>Vaginosis, Bacterial - drug therapy</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkFtPJCEQhYlZo66XX2BMP5h9a4WmoWHfdLLrJSbeRrPZF1LdDYr2NCMwXv69jD1RE5Kq1Pk4BQehLYL3CBZ8n5GyKtgSWiOMVjlnkvxIPWYiLwUVq-hnCA8YEyIwW0GrBONCEILXkDqEJmpvoctu4c72LtjwO7vSz1a_ZM5kY68hTnQfs_NptK4PGfRtduFiGs0vjTrb2yY1J32b6oAY57PxvfYwfdtAywa6oDcXdR3d_P0zHh3nZ-dHJ6ODs7yhksW8Te8xvAZT0NpQxmhRt5Uk6VeAQfJSN-lQ4LKV3AhWkUKWpC5ELQDThlV0Hf0afKfePc10iGpiQ6O7DnrtZkFxySQVJf8CG-9C8NqoqbcT8G-KYDWPUg1RJnBn4TirJ7r9hg3ZJWB3AUBICRgPfWPDF8cFwx_Y9oA9hOj8p1yWHPNqviYfZBuifv2UwT8qXtGKqeN__xU5wsXh9fhSndJ3SziSSg</recordid><startdate>199901</startdate><enddate>199901</enddate><creator>Joesoef, M. R.</creator><creator>Schmid, G. P.</creator><creator>Hillier, S. L.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199901</creationdate><title>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</title><author>Joesoef, M. R. ; Schmid, G. P. ; Hillier, S. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-d028f6baf23bf35532bd791514a0a964ec4ec3a69d96f85712941b28b8a03c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Bacterial diseases</topic><topic>Bacterial diseases of the genital system</topic><topic>Bacterial vaginosis</topic><topic>Biological and medical sciences</topic><topic>Cream</topic><topic>Dosage</topic><topic>Experimentation</topic><topic>Female</topic><topic>Gels</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Placebos</topic><topic>Pregnancy</topic><topic>Pregnancy outcome</topic><topic>Sexually transmitted diseases</topic><topic>Vaginosis, Bacterial - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joesoef, M. R.</creatorcontrib><creatorcontrib>Schmid, G. P.</creatorcontrib><creatorcontrib>Hillier, S. L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joesoef, M. R.</au><au>Schmid, G. P.</au><au>Hillier, S. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1999-01</date><risdate>1999</risdate><volume>28</volume><issue>Supplement-1</issue><spage>S57</spage><epage>S65</epage><pages>S57-S65</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>10028110</pmid><doi>10.1086/514725</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 1999-01, Vol.28 (Supplement-1), p.S57-S65
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_69593846
source MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Bacterial diseases
Bacterial diseases of the genital system
Bacterial vaginosis
Biological and medical sciences
Cream
Dosage
Experimentation
Female
Gels
Human bacterial diseases
Humans
Infections
Infectious diseases
Male
Medical sciences
Placebos
Pregnancy
Pregnancy outcome
Sexually transmitted diseases
Vaginosis, Bacterial - drug therapy
title Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T05%3A19%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bacterial%20Vaginosis:%20Review%20of%20Treatment%20Options%20and%20Potential%20Clinical%20Indications%20for%20Therapy&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Joesoef,%20M.%20R.&rft.date=1999-01&rft.volume=28&rft.issue=Supplement-1&rft.spage=S57&rft.epage=S65&rft.pages=S57-S65&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/514725&rft_dat=%3Cjstor_proqu%3E4460675%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69593846&rft_id=info:pmid/10028110&rft_jstor_id=4460675&rfr_iscdi=true